Company profile · Public records

Anthea Pharma

Free public records show Anthea Pharma in 1 of the markets we cover. It is not a key player in our research.

0Reports naming them
1Markets in public records
0Regions & countries
See reportsGrowth in full reports

Public data

Free public data on Anthea Pharma

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

US drug approvals

9 approvals with a product on the US market

Ketorolac Tromethamine ANDA221041 · approved 25 Sep 2026
Propofol ANDA220857 · approved 14 Jul 2026
Bupivacaine Hydrochloride ANDA220493 · approved 22 Apr 2026
Olanzapine ANDA220323 · approved 5 Mar 2026
Bumetanide ANDA220427 · approved 26 Feb 2026

Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.

See them on openFDA

Markets where public records show them

Markets we cover where free public records show Anthea Pharma: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Pain Management Drugs

Healthcare Topics

The topics of the markets Anthea Pharma is in.

All healthcare topics

Pain

From our blog

Stories on the topics Anthea Pharma works in.

All stories

Cannabis-Based Medicines: Science and Regulation

The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…

Read

Search all reports for Anthea Pharma All companies